Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, April 16, 2024
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy
Tuesday, September 12, 2023
SinoMab's IND Application of SM17 has once again Received Approval from NAMP
Monday, August 14, 2023
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP
Monday, June 12, 2023
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE
Monday, May 22, 2023
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE
Monday, December 19, 2022
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"
Friday, November 4, 2022
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company
Wednesday, August 24, 2022
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA
Friday, July 8, 2022
SinoMab Received the Highest Subsidy from HKSTP
Tuesday, June 21, 2022
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: